Christophe Queva Ph.D.
Net Worth
Last updated:
What is Christophe Queva Ph.D. net worth?
The estimated net worth of Dr. Christophe Queva Ph.D. is at least $2,932,469 as of 2 Jun 2021. He has earned $750,149 from insider trading and has received compensation worth at least $2,182,320 in Oncorus, Inc..
What is the salary of Christophe Queva Ph.D.?
Dr. Christophe Queva Ph.D. salary is $545,580 per year as Chief Scientific Officer & Senior Vice President of Research in Oncorus, Inc..
How old is Christophe Queva Ph.D.?
Dr. Christophe Queva Ph.D. is 57 years old, born in 1968.
What stocks does Christophe Queva Ph.D. currently own?
As insider, Dr. Christophe Queva Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Oncorus, Inc. (ONCR) | Chief Scientific Officer & Senior Vice President of Research | 47,626 | $0 | $0 |
What does Oncorus, Inc. do?
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Christophe Queva Ph.D. insider trading
Oncorus, Inc.
Dr. Christophe Queva Ph.D. has made 7 insider trades in 2021, according to the Form 4 filled with the SEC. Most recently he sold 10,656 units of ONCR stock worth $177,529 on 2 Jun 2021.
The largest trade he's ever made was exercising 35,561 units of ONCR stock on 24 May 2021. As of 2 Jun 2021 he still owns at least 47,626 units of ONCR stock.
Oncorus key executives
Oncorus, Inc. executives and other stock owners filed with the SEC:
- Dr. Christophe Queva Ph.D. (57) Chief Scientific Officer & Senior Vice President of Research
- Dr. Mitchell H. Finer Ph.D. (66) Co-Founder & Executive Chairman
- Dr. Theodore T. Ashburn (58) Pres, Chief Executive Officer & Director
- Mr. Stephen W. Harbin (67) Chief Operating Officer & Chief of Staff